Yang Y, Qiu L
Brain Sci. 2024; 14(6).
PMID: 38928590
PMC: 11201671.
DOI: 10.3390/brainsci14060590.
Deaton C, Johnson G
J Alzheimers Dis. 2020; 77(3):961-977.
PMID: 32804090
PMC: 8056533.
DOI: 10.3233/JAD-200598.
DArgenio V, Sarnataro D
J Pers Med. 2020; 10(2).
PMID: 32325882
PMC: 7354425.
DOI: 10.3390/jpm10020026.
Li Y, Yang Z, Zhang Y, Yang J, Shang D, Zhang S
Aging Dis. 2019; 10(4):908-914.
PMID: 31440394
PMC: 6675531.
DOI: 10.14336/AD.2018.1109.
Navarro E, de Andres C, Guerrero C, Gimenez-Roldan S
Mov Disord Clin Pract. 2019; 2(4):388-394.
PMID: 30838239
PMC: 6353493.
DOI: 10.1002/mdc3.12212.
The role of de novo mutations in adult-onset neurodegenerative disorders.
Nicolas G, Veltman J
Acta Neuropathol. 2018; 137(2):183-207.
PMID: 30478624
PMC: 6513904.
DOI: 10.1007/s00401-018-1939-3.
A pathogenic p.His169Asn mutation associated with early-onset Alzheimer's disease.
Giau V, Pyun J, Bagyinszky E, An S, Kim S
Clin Interv Aging. 2018; 13:1321-1329.
PMID: 30104866
PMC: 6074827.
DOI: 10.2147/CIA.S170374.
p.Met233Val in a Complex Neurodegenerative Movement and Neuropsychiatric Disorder.
Appel-Cresswell S, Guella I, Lehman A, Foti D, Farrer M
J Mov Disord. 2018; 11(1):45-48.
PMID: 29316780
PMC: 5790629.
DOI: 10.14802/jmd.17066.
APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases.
Lanoiselee H, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S
PLoS Med. 2017; 14(3):e1002270.
PMID: 28350801
PMC: 5370101.
DOI: 10.1371/journal.pmed.1002270.
A systematic screening to identify de novo mutations causing sporadic early-onset Parkinson's disease.
Kun-Rodrigues C, Ganos C, Guerreiro R, Schneider S, Schulte C, Lesage S
Hum Mol Genet. 2015; 24(23):6711-20.
PMID: 26362251
PMC: 4634375.
DOI: 10.1093/hmg/ddv376.
Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons.
Nicolas G, Wallon D, Charbonnier C, Quenez O, Rousseau S, Richard A
Eur J Hum Genet. 2015; 24(5):710-6.
PMID: 26242991
PMC: 4930083.
DOI: 10.1038/ejhg.2015.173.
De novo deleterious genetic variations target a biological network centered on Aβ peptide in early-onset Alzheimer disease.
Rovelet-Lecrux A, Charbonnier C, Wallon D, Nicolas G, Seaman M, Pottier C
Mol Psychiatry. 2015; 20(9):1046-56.
PMID: 26194182
DOI: 10.1038/mp.2015.100.
The genetics of Alzheimer's disease.
Bagyinszky E, Youn Y, An S, Kim S
Clin Interv Aging. 2014; 9:535-51.
PMID: 24729694
PMC: 3979693.
DOI: 10.2147/CIA.S51571.
The paradox of syndromic diversity in Alzheimer disease.
Warren J, Fletcher P, Golden H
Nat Rev Neurol. 2012; 8(8):451-64.
PMID: 22801974
DOI: 10.1038/nrneurol.2012.135.
The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment.
Tarawneh R, Holtzman D
Cold Spring Harb Perspect Med. 2012; 2(5):a006148.
PMID: 22553492
PMC: 3331682.
DOI: 10.1101/cshperspect.a006148.
Familial frontotemporal dementia-associated presenilin-1 c.548G>T mutation causes decreased mRNA expression and reduced presenilin function in knock-in mice.
Watanabe H, Xia D, Kanekiyo T, Kelleher 3rd R, Shen J
J Neurosci. 2012; 32(15):5085-96.
PMID: 22496554
PMC: 3340902.
DOI: 10.1523/JNEUROSCI.0317-12.2012.
Clinical picture of a patient with a novel PSEN1 mutation (L424V).
Robles A, Sobrido M, Garcia-Murias M, Prieto J, Lema M, Santos D
Am J Alzheimers Dis Other Demen. 2008; 24(1):40-5.
PMID: 19001354
PMC: 10846114.
DOI: 10.1177/1533317508324272.
Frontotemporal dementia-like phenotypes associated with presenilin-1 mutations.
Mendez M, McMurtray A
Am J Alzheimers Dis Other Demen. 2006; 21(4):281-6.
PMID: 16948293
PMC: 10833339.
DOI: 10.1177/1533317506290448.
Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene.
Larner A, Doran M
J Neurol. 2005; 253(2):139-58.
PMID: 16267640
DOI: 10.1007/s00415-005-0019-5.
